Paradoxical adverse effects of anti-TNF-α treatment: Onset or exacerbation of cutaneous disorders

Expert Review of Clinical Immunology

Volumn 5, Issue 4, 2009, Pages 421-431

  Viguier, Manuelle ^a   Richette, Pascal ^a   Bachelez, Hervé ^a   Wendling, Daniel ^b   Aubin, François ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Adalimumab; Anti TNF; Etanercept; Granuloma; Infliximab; Psoriasis; Sarcoidosis; Skin; Vasculitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETRETIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; KERATOLYTIC AGENT; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D DERIVATIVE;

ADVERSE OUTCOME; CLINICAL PRACTICE; DERMATITIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INTERSTITIAL GRANULOMATOUS DERMATITIS; LOW DRUG DOSE; LUNG NODULE; PARADOXICAL DRUG REACTION; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRACTICE GUIDELINE; PSORIASIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SKIN BIOPSY; SKIN DISEASE; SKIN NODULE; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 74249088181     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.18     Document Type: Review

References (80)

1. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as a monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022 (2003).
2. Gottlieb A, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51, 534-542 (2004).
3. Sfikakis PP, Iliopoulos A, Elezoglou A et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 52 (8), 2513-2518 (2005).
4. Ritchlin C, Tausk F. A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents. Ann. Rheum. Dis. 65, 1541-1544 (2006).
5. Sari I, Akar S, Birlik M et al. Anti-tumor necrosis factor-?-induced psoriasis. J. Rheumatol. 33, 1411-1414 (2006).
6. Kary S, Worm M, Audring H et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor αantagonists. Ann. Rheum. Dis. 65, 405-407 (2006).
7. De Gannes GC, Ghoreishi M, Pope J et al. Psoriasis and pustular dermatitis triggered by TNF-αinhibitors in patients with rheumatologic conditions. Arch. Dermatol. 143, 223-231 (2007).
8. Cohen JD, Bournerias I, Buffard V et al. Psoriasis induced by tumor necrosis factor-αantagonist therapy: a case series. J. Rheumatol. 34, 380-385 (2007).
9. Richette P, Viguier M, Bachelez H et al. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect? J. Rheumatol. 34, 438-439 (2007).
10. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 59(7), 996-1001 (2008).
11. Roé E, Puig L, Corella F, García-Navarro X, Alomar A. Cutaneous adverse effects of biological therapies for psoriasis. Eur. J. Dermatol. 18(6), 693-699 (2008).
12. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatolog. Treat. 16, 1-8 (2008).
13. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum. 37(4), 251-255 (2008).
14. Wendling D, Balblanc JC, Briançon D et al. Onset or exacerbation of cutaneous psoriasis during TNFαantagonist therapy. Joint Bone Spine 75(3), 315-318 (2008).
15. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-αantibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41, 1126-1132 (2002).
16. Lamprecht P, Voswinkel J, Lilienthal T et al. Effectiveness of TNF-αblockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41, 1303-1307 (2002).
17. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss- syndrome with TNF-αblockade. Immunobiology 206, 496-501 (2002).
18. Hoffman G, Merkel P, Brasington R, Lenschow D, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 50, 2296-2304 (2004).
19. Weiss J, Eberhard B, Chowdhury D, Gottlieb B. Infliximab as a novel therapy for refractory Kawasaki disease. J. Rheumatol. 31, 808-810 (2004).
20. Ohno S, Nakamura S, Hori S et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J. Rheumatol. 31, 1362-1368 (2004).
21. Berthelot JM, Glemarec J, Maugars Y, Prost A. Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis, Rheumatology (Oxford) 41, 703-705 (2002).
22. Livermore PA, Murray KJ. Anti-tumour necrosis factor therapy associated with cutaneous vasculitis. Rheumatology (Oxford) 41, 1450-1452 (2002).
23. Jarrett SJ, Cunnane G, Conaghan PG et al. Anti-tumor necrosis factor-αtherapyinduced vasculitis: case series. J. Rheumatol. 30, 2287-2291 (2003).
24. Mohan N, Edwards ET, Cupps TR et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-αblocking agents. J. Rheumatol. 31, 1955-1958 (2004).
25. Guillevin L, Mouthon L. Tumor necrosis factor-αblockade and the risk of vasculitis, J. Rheumatol. 31, 1885-1890 (2004).
26. Richette P, Dieude P, Damiano J, Liote F, Orcel P, Bardin T. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for RA. J. Rheumatol. 31, 2079-2081 (2004).
27. Roux CH, Brocq O, Albert C, Breuil V, Euller-Ziegler L. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF αagent etanercept for rheumatoid arthritis, Joint Bone Spine 71, 444-445 (2004). (Pubitemid 39335685)
28. Srivastava MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand. J. Immunol. 61, 329-336 (2005).
29. Mor A, Bingham 3rd C, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept, J. Rheumatol. 32, 740-743 (2005).
30. Wendling D, Streit G, Lehuede G et al. Cutaneous lymphocytic vasculitis during TNFαantagonist therapy for polyarthritis. Joint Bone Spine 73, 215-216 (2006).
31. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFα antagonists: a study in 39 patients in France. Joint Bone Spine 73, 710-713 (2006).
32. Fehrenbach H, Zissel G, Goldmann T et al. Alveolar macrophages are the main source for tumour necrosis factor-αin patients with sarcoidosis. Eur. Respir. J. 21(3), 421-428 (2003).
33. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 361, 1111-1118 (2003).
34. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J. Rheumatol. 30(8), 1864-1867 (2003).
35. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 127(3), 1064-1071 (2005).
36. Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum. 53(5), 788-791 (2005).
37. O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum. 55(6), 978-981 (2006).
38. Almodovar R, Izquierdo M, Zarco P, Javier Quiros F, Mazzucchelli R, Steen B. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin. Exp. Rheumatol. 25(1), 99-101 (2007).
39. Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-αtreatment for inflammatory rheumatic diseases: report of two cases. Clin. Exp. Rheumatol. 26(3), 471-475 (2008).
40. Gonzalez-Lopez MA, Blanco R, Gonzalez- Vela MC, Fernandez-Llaca H, Rodriguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 55(5), 817-820 (2006).
41. Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum. 53(4), 618-620 (2005).
42. Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin. Rheumatol. 26(11), 1969-1971 (2007). (Pubitemid 47516989)
43. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor αtherapy: a new 'class effect' paradoxical phenomenon. Two case reports and literature review. Semin. Arthritis Rheum. (2009) (Epub ahead of print).
44. Ishiguro T, Takayanagi N, Kurashima K et al. Development of sarcoidosis during etanercept therapy. Intern. Med. 47(11), 1021-1025 (2008).
45. Farah RE, Shay MD. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy 27(10), 1446-1448 (2007).
46. Kudrin A, Chilvers ER, Ginawi A et al. Sarcoid-like granulomatous disease following etanercept treatment for RA. J. Rheumatol. 34(3), 648-649 (2007).
47. Vavricka SR, Wettstein T, Speich R, Gaspert A, Bachli EB. Pulmonary granulomas after tumour necrosis factor αantagonist therapy. Thorax 58(3), 278-279 (2003).
48. Sturfelt G, Christensson B, Bynke G, Saxne T. Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J. Rheumatol. 34(11), 2313-2314 (2007). (Pubitemid 350076897)
49. Rott S, Mrowietz U. Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ 330, 716-720 (2005).
50. Harrison MJ, Dixon WG, Watson KD et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor αtherapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 68(2), 209-215 (2009).
51. Seneschal J, Lepreux S, Bouyssou-Gauthier ML et al. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. Acta Derm.Venereol. 87(1), 77-80 (2007). (Pubitemid 46225397)
52. Dutz JP. Tumor necrosis factor αinhibition and palmoplantar pustulosis: Janus-faced therapy? J. Rheumatol. 34, 247-249 (2007).
53. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soto MJ, BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87(6), 345-364 (2008).
54. Poulalhon N, Begon E, Lebbé C et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br. J. Dermatol. 156(2), 329-336 (2007).
55. Ramos-Casals M, Brito-Zerón P, Cuadrado MJ, Khamashta MA. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr. Rheumatol. Rep. 10(6), 442-448 (2008).
56. Ramos-Casals M, Brito-Zerón P, Muñoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86(4), 242-251 (2007).
57. De Miguel S, Jover J, Vadillo C, Judez E, Loza E, Fernandez-Gutierrez B. B cell activation in rheumatoid arthritis patients under infliximab treatment. Clin. Exp. Rheumatol. 21, 726-732 (2003).
58. Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with infliximab. J. Rheumatol. 30(12), 2557-2562 (2003).
59. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 128(2), 1062-1067 (2005).
60. Baughman RP, Drent M, Kavuru M et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. 174(7), 795-802 (2006).
61. Eishi Y, Suga M, Ishige I et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J. Clin. Microbiol. 40(1), 198-204 (2002).
62. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36(3), 159-167 (2006).
63. Barna BP, Culver DA, Abraham S et al. Depressed peroxisome proliferatoractivated receptor γ(PParγ) is indicative of severe pulmonary sarcoidosis: possible involvement of interferon γ(IFN-γ). Sarcoidosis Vasc. Diffuse Lung Dis. 23(2), 93-100 (2006).
64. Fayyazi A, Schwyer S, Eichmeyer B et al. Expression of IFNγ, coexpression of TNFαand matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. Arch. Dermatol. Res. 292, 384-390 (2000).
65. Hertl MS, Haendle I, Schuler G, Hertl M. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-αinhibitor, infliximab. Br. J. Dermatol. 152, 552-555 (2005).
66. Shupack J, Siu K. Resolving granuloma annulare with etanercept. Arch. Dermatol. 142, 394-395 (2006).
67. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-αmonoclonal antibody therapy. Dermatology 206, 388-390 (2003).
68. Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann. Rheum. Dis. 67, 567-570 (2008).
69. Kreuter A, Gambichler T, Altmeyer P. Infliximab therapy for interstitial dermatitis. J. Eur. Acad. Dermatol. Venereol. 21, 251-252 (2007).
70. Deng A, Harvey V, Sina B et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor αinhibitors. Arch. Dermatol. 142, 198-202 (2006).
71. Hu S, Cohen D, Murphy G, Mody E, Qureshi AA. Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept. Cutis 81, 336-338 (2008).
72. Edwards JC, Wilkinson LS, Pitsillides AA. Palisading cells of rheumatoid nodules: comparison with synovial intimal cells. Ann. Rheum. Dis. 52(11), 801-805 (1993).
73. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. 47(4), 445-449 (2002).
74. Mackley CL, Ostrov BE, Ioffreda MD. Accelerated cutaneous nodulosis during infliximab therapy in a patient with rheumatoid arthritis. J. Clin. Rheumatol. 10(6), 336-338 (2004).
75. Lacana E, Amur S, Mummanneni P, Zhao H, Frueh FW. The emerging role of pharmacogenomics in biologics. Clin. Pharmacol. Ther. 82, 466-471 (2007).
76. Hüffmeier U, Lascorz J, Böhm B et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J. Invest. Dermatol. 129, 355-358 (2009).
77. Zhang XJ, Huang W, Yang S et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat. Genet. 41, 205-210 (2009)
78. Nair RP, Duffin KC, Helms C et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat. Genet. 41, 199-204 (2009).
79. de Cid R, Riveira-Munoz E, Zeeuwen PL et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat. Genet. 41, 211-215 (2009).
80. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Safety-related regulatory actions for biologicals approved in the United States and in the European Union. JAMA 300, 1887-1896 (2008).